Drug Trial Radar · NCT01733316
Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 31, 2013
Primary completion
Feb 2015
Study completion Jul 10, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to gather information about the effectiveness (how well it works to treat cystinosis) and safety of a new form of cysteamine bitartrate called RP103, compared to the already-approved drug cystinosis patients are taking called Cystagon®. In cystinosis, the body builds up cystine. When taken regularly, the active ingredient of Cystagon® (cysteamine bitartrate) reduces cystine in the body. RP103 has the same active ingredient as Cystagon® and is designed to reduce cystine in a similar way that Cystagon® does. To decide if RP103 is better than Cystagon®, the study will look at two types of blood tests. One test is pharmacodynamics (PD), which measures the amount of white blood cell (WBC) cystine after taking study drug. WBC cystine is a laboratory test used to find out if cysteamine bitartrate is reducing cystine levels in the body. The second test is pharmacokinetics (PK), which measures the amount of cysteamine in the blood after taking the drug. RP103 is different from Cystagon®: Instead of the cysteamine bitartrate being absorbed from the stomach, RP103 is designed to be absorbed from the small intestine. This may make the effects of the drug last longer, so that it can be taken twice a day instead of four times a day like Cystagon®. Some cystinosis patients have bad breath (halitosis) when they take Cystagon®. Study participants who experience bad breath with Cystagon® will be asked if they would like to participate in an optional "halitosis substudy" to investigate this issue by collecting some extra PK blood samples.
Conditions
- Cystinosis
Interventions
RP103Drug
Cystagon®Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine ValuesTime frame: While taking Cystagon® (Months 1, 2, 3): within 15 minutes pre-morning (AM) and pre-non AM dose. During 3 months of RP103 (Months 5, 6, 7): 30 minutes post-AM and post-evening (PM) dose.
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
California Pacific Medical Center (CPMC) Research Institute
San Francisco, California
Stanford University Medical School
Stanford, California
Emory Children's Center
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Baylor College of Medicine / Texas Childrens Hospital
Houston, Texas
University Hospital of Leuven
Leuven, Belgium
Hospices Civils de Lyon
Lyon, France
Hôpital Necker-Enfants Malades
Paris, France
Hôpital Robert Debré
Paris, France
Ospedale Pediatrico Bambino Gesù
Rome, Italy
Radboud University Nijmegen Medical Center
Nijmegen, Netherlands
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
Great Ormond Street
London, United Kingdom
Guy's Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.